The article discusses the treatment of neovascular age-related macular degeneration (AMD), a condition that causes significant visual loss due to choroidal neovascularization and photoreceptor damage. Ranibizumab and bevacizumab, both targeted against vascular endothelial growth factor (VEGF), have shown promise in improving visual acuity in patients with neovascular AMD. Intravitreal administration of these drugs has been effective in reducing visual loss and improving visual acuity, as evidenced by multiple randomized controlled trials. The article also reviews the current treatments for AMD, including focal thermal laser, photodynamic therapy, and anti-VEGF treatments like pegaptanib. It highlights the advantages and potential complications of intravitreal injections, such as endophthalmitis and ocular inflammation. Additionally, the article explores the use of bevacizumab, a commercially available compound, and its potential applications in other ocular conditions. The future directions in AMD treatment are discussed, emphasizing the need for combination therapies and the development of new treatments. Overall, the article underscores the significant advancements in managing neovascular AMD and the ongoing research to optimize treatment strategies.The article discusses the treatment of neovascular age-related macular degeneration (AMD), a condition that causes significant visual loss due to choroidal neovascularization and photoreceptor damage. Ranibizumab and bevacizumab, both targeted against vascular endothelial growth factor (VEGF), have shown promise in improving visual acuity in patients with neovascular AMD. Intravitreal administration of these drugs has been effective in reducing visual loss and improving visual acuity, as evidenced by multiple randomized controlled trials. The article also reviews the current treatments for AMD, including focal thermal laser, photodynamic therapy, and anti-VEGF treatments like pegaptanib. It highlights the advantages and potential complications of intravitreal injections, such as endophthalmitis and ocular inflammation. Additionally, the article explores the use of bevacizumab, a commercially available compound, and its potential applications in other ocular conditions. The future directions in AMD treatment are discussed, emphasizing the need for combination therapies and the development of new treatments. Overall, the article underscores the significant advancements in managing neovascular AMD and the ongoing research to optimize treatment strategies.